Physician profile
Misha Peter
NPI 1245478239
$8,730.29
in general payments reported to CMS, 2019-2025
38 companies · $1,632 in 2025
The $1,632 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $748 · 2020: $878 · 2021: $1,078 · 2022: $847 · 2023: $2,639 · 2024: $908 · 2025: $1,632.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,220 · Travel and Lodging: $794 · Education: $165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,219.96 |
| Travel and Lodging | $794.13 |
| Education | $164.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Imbed Biosciences INC. | $1,571.26 | 2023 | |
| Glaxosmithkline, LLC. | $1,249.69 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Inspire Medical Systems, INC. | $1,055.24 | 2022-2025 | Inspire |
| Astrazeneca Pharmaceuticals Lp | $818.90 | 2019-2025 | Airsupra, Breztri, Fasenra |
| Mylan Specialty L.P. | $763.80 | 2019-2024 | Yupelri |
| Harmony Biosciences LLC | $446.31 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $364.61 | 2019-2025 | Ofev |
| Regeneron Healthcare Solutions, INC. | $291.65 | 2019-2025 | Dupixent |
| Janssen Pharmaceuticals, INC | $226.33 | 2021-2024 | Xarelto |
| Zoll Respicardia, INC. | $211.48 | 2023 | Remede System |
| Grifols USA, LLC | $174.74 | 2020-2025 | Prolastin-C Liquid |
| Jazz Pharmaceuticals INC. | $152.96 | 2020-2025 | |
| Amgen INC. | $138.40 | 2022-2025 | Tezspire |
| Fisher & Paykel Healthcare INC | $133.78 | 2021-2025 | Fisher & Paykel Healthcare |
| Electromed, INC. | $126.95 | 2023-2025 | Smartvest |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $120.61 | 2019-2025 | Vest Therapy Und, Home Pi Undivided |
| Genzyme Corporation | $107.45 | 2019-2025 | |
| Genentech USA, INC. | $87.73 | 2019-2023 | Xolair |
| Gilead Sciences, INC. | $80.04 | 2021-2023 | Veklury |
| Actelion Pharmaceuticals US, INC. | $77.23 | 2019-2020 | |
| United Therapeutics Corporation | $76.30 | 2020-2024 | Tyvaso |
| Baxter Healthcare | $57.60 | 2023-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Mallinckrodt Hospital Products INC. | $42.42 | 2024-2025 | Acthar |
| Ani Pharmaceuticals, INC. | $39.97 | 2025 | Purified Cortrophin Gel |
| Insmed, INC. | $39.82 | 2023-2025 | Arikayce |
| Tactile Systems Technology INC | $38.54 | 2024 | Flexitouch Plus, Entre Plus |
| Itamar Medical INC | $25.77 | 2022 | |
| Advanced Respiratory, INC | $24.22 | 2021 | |
| Verona Pharma, INC. | $22.79 | 2025 | Ohtuvayre |
| Novartis Pharmaceuticals Corporation | $22.17 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.15 | 2021 | |
| Axsome Therapeutics, INC. | $22.12 | 2024 | Sunosi |
| Bayer Healthcare Pharmaceuticals INC. | $20.16 | 2019 | |
| Circassia INC. | $19.13 | 2019 | |
| Azurity Pharmaceuticals, INC. | $15.58 | 2024 | Horizant |
| Resmed Corp | $15.36 | 2025 | |
| Portola Pharmaceuticals, LLC | $14.16 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Misha Peter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.